Coil Embolization for Coronary Artery Perforation: A Retrospective Analysis of 110 Patients

Table 3

Medication and outcomes after percutaneous coronary intervention.

	110 patients
Medication
Aspirin, n (%)	108 (99.1%)
Ticlopidine, n (%)	4 (3.7%)
Clopidogrel, n (%)	44 (40.4%)
Prasugrel, n (%)	55 (50.5%)
Ticagrelor, n (%)	0 (0%)
Cilostazol, n (%)	5 (4.6%)
Warfarin, n (%)	10 (9.2%)
DOAC, n (%)	13 (11.8%)
Single APT	0 (0%)
Single APT + OAC	3 (2.7%)
Dual APT	95 (86.4%)
Dual APT + OAC	9 (8.2%)
Triple APT	1 (0.1%)
Only DOAC	1 (0.1%)
Clinical outcomes
In-hospital death, n (%)	2 (1.8%)
Creatine kinase of the next day (U/L)	352 ± 404
Postprocedural MI, n (%)	6 (5.5%)
Left ventricular EF of the next day (%)	57.1 ± 12.1
EF changes from baseline to follow-up (%)	0.69 ± 8.05

Values are expressed as numbers (%) or means (±SD). APT, antiplatelet therapy; OAC, oral anticoagulants; DOAC, direct oral anticoagulants; MI, myocardial infarction; EF, ejection fraction.